ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA grants fast track designation to Cerecor’s Covid-19 treatment
May 12, 2021The US Food and Drug Administration (FDA) has granted fast track designation to Cerecor’s fully human monoclonal antibody (mAb), CERC-002, for treating hospitalised Covid-19 patients. -
Cerecor’s antibody reduces respiratory failure in Covid-19 ARDS trial
March 03, 2021Cerecor has reported that final efficacy data from Phase II trial of human anti-LIGHT (TNFSF14) monoclonal antibody, CERC-002, in hospitalised patients with Covid-19 linked pneumonia and mild-to-moderate acute respiratory distress syndrome (ARDS) met ... -
Cerecor CEO retires after scoring Johnson & Johnson license deal
August 16, 2017J&J is paying $25 million upfront for rights to CERC-501.
Pharma Sources Insight January 2025
